Grant ID RP200381
Awarded On February 19, 2020
Title Doxorubicin-Induced Cardiotoxicity: Defining Blood and Echocardiogram Biomarkers in a Mouse Model and AYA Sarcoma Patients for Evaluating Exercise Interventions
Program Academic Research
Award Mechanism Individual Investigator Research Awards for Cancer in Children and Adolescents
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Eugenie S Kleinerman
Cancer Sites Bone
Contracted Amount $1,444,593*

*Pending contract negotiation

Lay Summary

Adolescent and young adult (AYA) sarcoma patients treated with doxorubicin (Dox) are 8.2 times more likely to develop heart failure later in life. We developed an adolescent cardiotoxicity mouse model and showed that exercise decreased acute Dox-induced heart damage and late cardiotoxicity without decreasing tumor efficacy. We wish to define a set of echo and blood biomarkers in patients that can be used to identify patients at risk for cardiotoxicity and for use in a randomized trial to evaluate the clinical effectiveness of exercise in the AYA sarcoma population. The long-term goal is to reduce acute Dox-induced cardiac injury and late cardiomyopathy. Since Dox-induced cardiotoxicity is t...

Read More